Join our expert panel where they will discuss inflammatory bowel disease and NASH, two therapeutic areas that histopathology uses to determine eligibility and/or primary outcome measures. Our four experts will provide presentations on topics including Histopathology as a treatment target in IBD: Aspiration or Reality? Measuring histopathology in IBD trials Histopathology as a treatment target in NASH trials Measuring histopathology in NASH trials Followed by a panel discussion including questions from our viewers, led by Dr. Vipul Jairath, Chief Medical Officer, Alimentiv Inc.

discoveryaccelerated.com